World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult—a summary statement from the Pulmonary …

…, S Murali, RP Frantz, D McGlothlin, EM Horn… - The Journal of heart and …, 2012 - Elsevier
Pulmonary hypertension associated with left heart disease is the most common form of
pulmonary hypertension encountered in clinical practice today. Although frequently a target of …

Evaluation and management of pulmonary hypertension in noncardiac surgery: a scientific statement from the American Heart Association

S Rajagopal, K Ruetzler, K Ghadimi, EM Horn… - Circulation, 2023 - Am Heart Assoc
Pulmonary hypertension, defined as an elevation in blood pressure in the pulmonary arteries,
is associated with an increased risk of death. The prevalence of pulmonary hypertension …

[HTML][HTML] Clinical characteristics of Covid-19 in New York city

…, E Reshetnyak, N Hupert, EM Horn… - … England Journal of …, 2020 - Mass Medical Soc
Covid-19 in New York City In this series of 393 consecutive patients admitted with Covid-19
to two New York City hospitals from March 3 to March 27, a third of patients received …

Suprapontine control of respiration

EM Horn, TG Waldrop - Respiration physiology, 1998 - Elsevier
Despite focus on brainstem areas in central respiratory control, regions rostral to the medulla
and pons are now recognized as being important in modulating respiratory outflow during …

Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2

…, A Boonstra, LJ Rubin, EM Horn… - European …, 2004 - Eur Respiratory Soc
The efficacy and safety of combining bosentan, an orally active dual endothelin receptor
antagonist and epoprostenol, a continuously infused prostaglandin, in the treatment of …

Sitaxsentan therapy for pulmonary arterial hypertension

RJ Barst, D Langleben, A Frost, EM Horn… - American journal of …, 2004 - atsjournals.org
Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the
vasoconstrictor effects of endothelin-A while maintaining the vasodilator/clearance functions of …

[BOOK][B] Building blocks

SR Sandall, IS Schwartz, GE Joseph, EM Horn… - 2008 - brookespublishing.com
Horn is a professor and investigator at the University of Kansas (KU). She has worked in
early care and education, in the early childhood special education (ECSE) community, and in …

[PDF][PDF] Clinical risk factors for portopulmonary hypertension

…, RL Benza, DB Badesch, DB Taichman, EM Horn… - …, 2008 - Wiley Online Library
Portopulmonary hypertension affects up to 6% of patients with advanced liver disease, but
the predictors and biologic mechanism for the development of this complication are unknown. …

New predictors of outcome in idiopathic pulmonary arterial hypertension

SM Kawut, EM Horn, KK Berekashvili… - The American journal of …, 2005 - Elsevier
Idiopathic pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis.
New therapies have improved the outcome of this condition; accordingly, the factors that …

A randomised trial of endoscopic submucosal dissection versus endoscopic mucosal resection for early Barrett's neoplasia

G Terheggen, EM Horn, M Vieth, H Gabbert, M Enderle… - Gut, 2017 - gut.bmj.com
Background For endoscopic resection of early GI neoplasia, endoscopic submucosal
dissection (ESD) achieves higher rates of complete resection (R0) than endoscopic mucosal …